Home » Stocks » CNTA

Centessa Pharmaceuticals Limited (CNTA)

Stock Price: $20.64 USD -0.43 (-2.04%)
Updated Jul 30, 2021 4:00 PM EDT - Market closed
Market Cap 1.80B
Revenue (ttm) n/a
Net Income (ttm) -51.58M
Shares Out 87.42M
EPS (ttm) -0.59
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 30
Last Price $20.64
Previous Close $21.07
Change ($) -0.43
Change (%) -2.04%
Day's Open 20.88
Day's Range 20.26 - 21.15
Day's Volume 90,594
52-Week Range 19.61 - 26.90


Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

If two heads are better than one, consider what 10 can accomplish. That's the thinking behind Centessa Pharmaceuticals ( CNTA , Financial), a company constructed from the merger of 10 small drug companies.

1 month ago - GuruFocus

If two heads are better than one, consider what ten can accomplish.

1 month ago - GuruFocus

CAMBRIDGE, Mass. and LONDON, June 07, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced today that Saurabh Saha, M.D., Ph.D., Chief Executive Officer, will participate in an...

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass. and LONDON, June 04, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (“Centessa”), a clinical-stage company employing its innovative asset-centric business model to discover, deve...

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass. & LONDON--(BUSINESS WIRE)--Centessa Announces Pricing of Initial Public Offering

2 months ago - Business Wire

Centessa Pharmaceuticals, with four clinical and a dozen preclinical programs, expects its initial public offering to be slightly over the $250 million raised in a January series A. The largest single r...

2 months ago - FierceBiotech

Centessa Pharmaceuticals Limited has filed to go public with an IPO on the NASDAQ.

3 months ago - SEC

About CNTA

Centessa Pharmaceuticals was conceived by combining the primary strengths of the asset-centric model with the benefits of diversification and scale typically attributed to traditional large R&D organizations. The asset-centric model refers to single-purpose companies which are focused on developing a single program or programs associated with a single biological pathway. We have implemented this reimagined approach to R&D by initially combining a curated portfolio of ten wholly-owned asset-centric companies, which we refer to as the Centessa Su... [Read more...]

IPO Date
May 28, 2021
Saurabh Saha, M.D., Ph.D.
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for CNTA is 38.00, which is an increase of 84.11% from the latest price.

Price Target
(84.11% upside)